Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
TEVA PHARMA Dec-13 |
DISHMAN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,058 | - | |
Low | Rs | 129 | 2,656 | - | |
Sales per share (Unadj.) | Rs | 197.8 | 1,755.0 | - | |
Earnings per share (Unadj.) | Rs | 21.2 | 109.6 | - | |
Cash flow per share (Unadj.) | Rs | 34.7 | 251.5 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 95.97 | - | |
Dividend yield (eoy) | % | 0.8 | 3.4 | 23.7% | |
Book value per share (Unadj.) | Rs | 179.9 | 1,949.4 | - | |
Shares outstanding (eoy) | m | 80.69 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 78.1% | |
Avg P/E ratio | x | 11.9 | 26.1 | 45.5% | |
P/CF ratio (eoy) | x | 7.2 | 11.4 | 63.8% | |
Price / Book Value ratio | x | 1.4 | 1.5 | 95.4% | |
Dividend payout | % | 9.4 | 87.5 | 10.8% | |
Avg Mkt Cap | Rs m | 20,306 | 2,422,855 | 0.8% | |
No. of employees | `000 | 0.8 | 44.9 | 1.8% | |
Total wages/salary | Rs m | 5,355 | 0 | - | |
Avg. sales/employee | Rs Th | 19,252.7 | 33,111.7 | 58.1% | |
Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
Avg. net profit/employee | Rs Th | 2,064.1 | 2,068.5 | 99.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 1,488,204 | 1.1% | |
Other income | Rs m | 265 | 0 | - | |
Total revenues | Rs m | 16,226 | 1,488,204 | 1.1% | |
Gross profit | Rs m | 4,103 | 407,545 | 1.0% | |
Depreciation | Rs m | 1,091 | 120,293 | 0.9% | |
Interest | Rs m | 944 | 29,231 | 3.2% | |
Profit before tax | Rs m | 2,334 | 258,022 | 0.9% | |
Minority Interest | Rs m | 0 | 1,172 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -169,377 | 0.0% | |
Tax | Rs m | 624 | -3,150 | -19.8% | |
Profit after tax | Rs m | 1,711 | 92,967 | 1.8% | |
Gross profit margin | % | 25.7 | 27.4 | 93.9% | |
Effective tax rate | % | 26.7 | -1.2 | -2,188.8% | |
Net profit margin | % | 10.7 | 6.2 | 171.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 1,005,127 | 1.1% | |
Current liabilities | Rs m | 9,517 | 876,556 | 1.1% | |
Net working cap to sales | % | 9.4 | 8.6 | 108.8% | |
Current ratio | x | 1.2 | 1.1 | 101.0% | |
Inventory Days | Days | 110 | 91 | 121.7% | |
Debtors Days | Days | 35 | 96 | 36.3% | |
Net fixed assets | Rs m | 16,304 | 486,080 | 3.4% | |
Share capital | Rs m | 161 | 3,663 | 4.4% | |
Net worth | Rs m | 14,516 | 1,653,112 | 0.9% | |
Long term debt | Rs m | 4,189 | 760,952 | 0.6% | |
Total assets | Rs m | 29,805 | 3,401,022 | 0.9% | |
Interest coverage | x | 3.5 | 9.8 | 35.3% | |
Debt to equity ratio | x | 0.3 | 0.5 | 62.7% | |
Sales to assets ratio | x | 0.5 | 0.4 | 122.4% | |
Return on assets | % | 8.9 | 3.6 | 248.0% | |
Return on equity | % | 11.8 | 5.6 | 209.6% | |
Return on capital | % | 17.5 | 4.9 | 355.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 237,143 | 1.2% | |
From Investments | Rs m | -1,529 | -84,029 | 1.8% | |
From Financial Activity | Rs m | -941 | -284,469 | 0.3% | |
Net Cashflow | Rs m | 316 | -131,355 | -0.2% |
Compare DISHMAN PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare DISHMAN PHARMA With: AUROBINDO PHARMA VENUS REMEDIES DR. REDDYS LAB DR. DATSONS LABS DIVIS LABORATORIES
Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More